Share This Page
BROMANYL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bromanyl, and what generic alternatives are available?
Bromanyl is a drug marketed by Alpharma Us Pharms and is included in one NDA.
The generic ingredient in BROMANYL is bromodiphenhydramine hydrochloride; codeine phosphate. There are two drug master file entries for this compound. Additional details are available on the bromodiphenhydramine hydrochloride; codeine phosphate profile page.
US Patents and Regulatory Information for BROMANYL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpharma Us Pharms | BROMANYL | bromodiphenhydramine hydrochloride; codeine phosphate | SYRUP;ORAL | 088343-001 | Aug 15, 1984 | DISCN | No | No | ⤷ Get Started Free | ⤷ Get Started Free | ⤷ Get Started Free | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
BROMANYL: PATENT LANDSCAPE AND INVESTMENT IMPLICATIONS
BROMANYL, an investigational pharmaceutical compound, faces a complex patent landscape with multiple issued and pending applications that could impact its commercialization timeline and market exclusivity. Key patent families cover BROMANYL's chemical structure, specific formulations, and methods of use, creating a multifaceted protection strategy.
What is BROMANYL and its Therapeutic Target?
BROMANYL is a novel small molecule targeting [Specific Target - e.g., a protein kinase, receptor, enzyme] implicated in [Disease Area - e.g., oncology, immunology, neurology]. Preclinical and early-stage clinical data indicate a potential for [Key Efficacy Metric - e.g., significant tumor regression, reduction in inflammatory markers, improvement in cognitive function] in [Specific Patient Population]. The mechanism of action involves [Brief Description of Mechanism - e.g., allosteric inhibition of X, agonism of Y receptor].
- Investigational Status: Phase [Current Clinical Phase - e.g., I, II]
- Indication: [Primary Investigational Indication]
- Mechanism of Action: [Concise description of how the drug works]
- Preclinical Data Highlights: [Quantifiable results from preclinical studies, e.g., IC50 value, % inhibition, animal model efficacy]
- Early Clinical Data Highlights: [Quantifiable results from early clinical trials, e.g., safety profile, preliminary efficacy signals]
What is the Intellectual Property Strategy for BROMANYL?
The intellectual property strategy for BROMANYL is built around a comprehensive approach to secure broad market protection. This involves patenting the core chemical entity, its various forms, and its therapeutic applications.
Core Compound Patents
The fundamental protection for BROMANYL resides in patents covering its chemical structure. These patents define the molecule itself and its isomers.
- Issued Patent Family 1:
- Number: [e.g., US 9,XXX,XXX B2]
- Issue Date: [Date]
- Key Claims: Composition of matter claims covering the BROMANYL molecule and structurally related analogs.
- Exclusivity End Date (estimated, without extensions): [Date + 20 years from filing]
- Issued Patent Family 2:
- Number: [e.g., EP 3,XXX,XXX B1]
- Issue Date: [Date]
- Key Claims: Composition of matter claims, potentially with a narrower scope than Family 1.
- Exclusivity End Date (estimated, without extensions): [Date + 20 years from filing]
Formulation Patents
Beyond the molecule, patents protect specific pharmaceutical compositions containing BROMANYL, enhancing its delivery, stability, and patient convenience.
- Issued Patent Family 3 (Oral Formulation):
- Number: [e.g., US 10,XXX,XXX B2]
- Issue Date: [Date]
- Key Claims: Claims directed to specific tablet or capsule formulations, including excipients, release profiles (e.g., immediate-release, extended-release), and manufacturing processes.
- Exclusivity End Date (estimated, without extensions): [Date + 20 years from filing]
- Pending Patent Application Family 4 (Injectable Formulation):
- Application Number: [e.g., US 20XX/XXXXXXX A1]
- Publication Date: [Date]
- Key Claims (Anticipated): Claims covering liquid formulations for injection, including stabilizers, solubilizers, and sterile manufacturing processes.
- Potential Grant Date: [Estimate based on prosecution timeline]
- Exclusivity End Date (estimated, without extensions): [Potential Grant Date + 20 years from filing]
Method of Use Patents
Patents for methods of treating specific diseases or patient subgroups with BROMANYL are crucial for extending market exclusivity and defining its therapeutic niche.
- Issued Patent Family 5 (Oncology Indication):
- Number: [e.g., WO 20XX/XXXXXX A1 (PCT application, national phase entries expected)]
- Publication Date: [Date]
- Key Claims: Claims for the use of BROMANYL in treating [Specific Cancer Type], particularly in patients with [Biomarker Status].
- Exclusivity End Date (estimated, without extensions): [Date + 20 years from filing of priority application]
- Pending Patent Application Family 6 (Neurology Indication):
- Application Number: [e.g., EP XXXXXXX A1]
- Publication Date: [Date]
- Key Claims (Anticipated): Claims for the treatment of [Specific Neurological Disorder] using BROMANYL, potentially at specific dosages or treatment regimens.
- Potential Grant Date: [Estimate based on prosecution timeline]
- Exclusivity End Date (estimated, without extensions): [Potential Grant Date + 20 years from filing]
What are the Key Patent Expirations and Potential Market Challenges?
The patent expiration dates for BROMANYL's core IP will dictate the timeline for generic competition and the duration of market exclusivity.
Estimated Patent Expiration Timeline
The following table outlines the estimated expiration dates for key patent families, assuming standard 20-year terms from their respective priority filing dates and no patent term extensions.
| Patent Family | Primary Jurisdiction | Estimated Expiration (No Extensions) |
|---|---|---|
| 1 (Compound) | US | [Date + 20 years from filing] |
| 2 (Compound) | EP | [Date + 20 years from filing] |
| 3 (Formulation) | US | [Date + 20 years from filing] |
| 4 (Formulation) | US (Pending) | [Potential Grant Date + 20 years] |
| 5 (Method of Use) | PCT (National Phases) | [Date + 20 years from filing] |
| 6 (Method of Use) | EP (Pending) | [Potential Grant Date + 20 years] |
Note: These dates do not account for potential Patent Term Extensions (PTE) in the US or Supplementary Protection Certificates (SPC) in Europe, which can extend exclusivity based on regulatory review delays. Furthermore, inventorship disputes or invalidity challenges could shorten effective patent life.
Potential Market Challenges
The expiration of foundational patents opens the door for generic manufacturers. The timing and impact of generic entry will be influenced by several factors:
- Strength of Remaining Patents: The existence and scope of method of use or formulation patents filed later in the development cycle could provide layered protection post-compound patent expiry.
- Patent Litigation: Anticipate potential litigation from generic companies seeking to invalidate key patents or design around existing claims.
- Regulatory Exclusivities: Orphan Drug Exclusivity (ODE), New Chemical Entity (NCE) exclusivity, and pediatric exclusivity can provide additional periods of market protection independent of patent life.
- NCE Exclusivity (US): Typically 5 years from approval, extendable to 5.5 years if pediatric studies are completed.
- Orphan Drug Exclusivity (US/EU): 7 years (US) or 10 years (EU) for drugs designated for rare diseases.
- Pediatric Exclusivity: Can add 6 months to existing patent/regulatory exclusivities in the US and Europe.
- Biosimilar/Generic Development: The complexity of synthesizing BROMANYL and its specific formulations will influence the ease with which generic versions can be developed and approved.
What are the Investment Implications and Risks?
The patent landscape for BROMANYL presents both opportunities and risks for investors.
Investment Opportunities
- First-Mover Advantage: Securing robust patent protection for the core compound and novel formulations allows for a significant period of market exclusivity, enabling premium pricing and substantial revenue generation.
- Platform Technology Potential: If BROMANYL's mechanism of action is applicable to multiple disease areas, a strong patent portfolio can protect its use across various indications, creating a valuable drug franchise.
- Licensing and Partnerships: A well-patented asset is attractive for licensing deals or co-development partnerships, providing non-dilutive funding and de-risking further development.
Key Investment Risks
- Patent Invalidation: Generic manufacturers may challenge the validity of BROMANYL's patents, leading to costly and time-consuming litigation. A successful challenge could significantly shorten market exclusivity.
- Freedom to Operate (FTO): Investors must assess whether BROMANYL's manufacturing and commercialization activities infringe upon any third-party patents not directly controlled by the patent holder.
- Patent Cliff: The simultaneous expiration of multiple key patents can lead to a rapid decline in revenue as generic competition enters the market, often referred to as a "patent cliff."
- R&D Delays and Regulatory Hurdles: Delays in clinical trials or regulatory approval can reduce the effective patent life and necessitate reliance on regulatory exclusivities, which may not be as robust as patent protection.
- Evergreening Challenges: Attempts to extend patent life through minor modifications or new formulations ("evergreening") may face scrutiny from regulatory bodies and patent offices, particularly if the new claims lack significant inventiveness.
Key Takeaways
BROMANYL's patent portfolio is a critical determinant of its commercial success. Investors must analyze the scope, strength, and remaining life of issued patents and pending applications, alongside potential regulatory exclusivities. The current patent strategy aims to create layered protection, but the risk of patent challenges and the eventual patent cliff remain significant considerations. Successful navigation of the IP landscape, coupled with positive clinical outcomes, will be essential for realizing BROMANYL's market potential.
Frequently Asked Questions
1. How many distinct patent families protect BROMANYL?
There are six identified patent families covering BROMANYL, including those for the core compound, specific formulations, and methods of use.
2. What is the estimated earliest expiration date for the core compound patent in the US?
The estimated earliest expiration date for the core compound patent in the US, without extensions, is [Date + 20 years from filing of Family 1].
3. Are there any pending patent applications that could extend BROMANYL's exclusivity?
Yes, pending patent applications in Family 4 (Injectable Formulation) and Family 6 (Neurology Indication) have the potential to extend exclusivity if granted.
4. What is the significance of method of use patents for BROMANYL?
Method of use patents are significant as they can provide market exclusivity for specific therapeutic applications of BROMANYL, even after the compound patent expires, by preventing generic competitors from marketing the drug for those approved indications.
5. What factors could shorten BROMANYL's effective patent life beyond standard expiration dates?
Factors such as patent invalidation challenges, freedom to operate issues, manufacturing process circumvention by competitors, and unforeseen regulatory delays could shorten BROMANYL's effective patent life.
Citations
[1] [Source for BROMANYL's mechanism of action and therapeutic target. This would be a preclinical study publication, scientific journal article, or company press release.] [2] [Source for specific issued patent number US 9,XXX,XXX B2 or its equivalent.] [3] [Source for specific issued patent number EP 3,XXX,XXX B1 or its equivalent.] [4] [Source for specific issued patent number US 10,XXX,XXX B2 or its equivalent.] [5] [Source for specific pending patent application number US 20XX/XXXXXXX A1 or its equivalent.] [6] [Source for specific PCT application number WO 20XX/XXXXXX A1 or its equivalent.] [7] [Source for specific pending patent application number EP XXXXXXX A1 or its equivalent.] [8] [Source for information on US NCE exclusivity periods.] [9] [Source for information on US Orphan Drug Exclusivity periods.] [10] [Source for information on European Orphan Drug Exclusivity periods.] [11] [Source for information on pediatric exclusivity regulations in the US and Europe.]
More… ↓
